The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2020 | Examples of biology informing treatment decisions in CLL
Kostas Stamatopoulos, MD, PhD, of the Center for Research and Technology Hellas, Thermi, Greece, discusses how a greater understanding of disease biology can inform treatment decisions in chronic lymphocytic leukemia (CLL), including ribosomal profiling of patients treated with ibrutinib as well as the significance of aberrant p53 signalling in CLL. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
